Dr. Andrea L. Wayda

Partner

Three World Financial Center
New York, New York 10281-2101
Phone: (212) 415-8552
Fax: (212) 303-2754
awayda@lockelord.com

Dr. Andrea L. Wayda is a partner in Locke Lord LLP's New York office. Her practice focuses on trial and appellate litigation as well as counseling in the chemical, pharmaceutical and medical device fields.

Dr. Wayda's prior career as a Member of Technical Staff at AT&T Bell Laboratories combined with her extensive experience in all phases of patent law enables her to provide high level technical advice and legal counseling to her clients. Dr. Wayda has participated in numerous patent trials in the U.S. District Courts in a range of and chemical, pharmaceutical and medical product disciplines including herbicides, zeolites, vaccine technology, hip implants, reduced circumference cigarettes, low-emission gasoline and various generic pharmaceuticals. Dr. Wayda's experience also includes the full range of patent prosecution practice (including re-examination and reissue proceedings and arguing appeals before the Board). Dr. Wayda has rendered opinions on validity and infringement in the chemical and medical device fields and also oversees and coordinates the global legal and business strategy for a major specialty metal company.

Education

J.D., New York University School of Law, 1992
American Jurisprudence Award in Criminal Procedure, May 1991
Ph.D., Inorganic Chemistry (Organometallic Chemistry), University of Chicago, 1981
S.B., Chemistry, University of Chicago, 1976
University Scholar, 1972-76

Bar Admissions

New York
New Jersey

Admitted To Practice

U.S. Court of Appeals for the Federal Circuit
U.S. Court of Federal Claims
U.S. Patent and Trademark Office

Representative Experience

Eli Lilly & Co. v. Actavis Elizabeth LLC et al., Case No. 07-CV-3770 (represented defendant Apotex in successfully invalidating Lilly's patent-in-suit directed to Lilly's ADHD drug Strattera in the District Ct. of NJ)
Purdue Pharma L.P., the P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. v. KV Pharmaceutical Company, MDL Action No. 1:04-MC-01603-SHS; Civil Action Nos. 07-CV-3972, 07-CV-3973 and 07-CV-4810 (SHS) (represented defendant, cases originally filed in the District of Delaware in 2006 and the S.D.N.Y in 2007; consolidated for discovery in the MDL in the S.D.N.Y., Paragraph IV ANDA case re: OxyContin).
In re: Rembrandt Technologies, L.P. Patent Litigation, Rembrandt Technologies, L.P. v. Fox, ABC, NBC and CBS; MDL Action No. 07-md-1848 (GMS); (represented plaintiff in four separate suits against broadcasters; originally filed in the District of Delaware in 2006 and consolidated with other cases for discovery in the MDL in Delaware).
Kollmorgen Corporation v. United States of America, No. 04-1661 C, (Represented Kollmorgen in the Court of Federal Claims in case settled by the parties in 2006 involving alleged infringement of Kollmorgen’s patent directed to remote operated small arms weapons mounts.)
Purdue Pharma L.P. v. Boehringer Ingelheim GmbH, Civil Action No. 99-3658 (S.D.N.Y. 2004) (Represented Boehringer Ingelheim GmbH in action involving sustained release formulation of oxycodone where Purdue’s patents were ruled unenforceable due to Purdue’s inequitable conduct in prosecuting patents in the United States Patent and Trademark Office; case is now on remand.)
Brown & Williamson Tobacco Corporation v. Phillip Morris Incorporated, 229 F.3d 1120 (Fed. Cir. 2000) (represented Brown & Williamson Tobacco Corp. ("B&W") in bench trial and appeal involving alleged infringement of B&W's patent directed to reduced circumference cigarettes).
E.I. du Pont de Nemours & Company v. Millennium Chemicals, Inc., 1999 U.S. Dist. LEXIS 12447 (D. Del. 1999) (Represented E.I. du Pont de Nemours & Company (“E.I. du Pont”) in case settled by the parties involving alleged infringement of E.I. du Pont’s patents directed to titanium dioxide pigments treated with organosilicon compounds).
Union Oil Company Of California v. Atlantic Richfield Company, 1998 U.S. Dist. LEXIS 22847 (C.D. Cal. March 10, 1998), aff’d, 208 F.3d 989 (Fed. Cir. 2000) (Represented Atlantic Richfield Company, Chevron U.S.A. Inc., Exxon Corporation, Mobil Oil Corporation, Shell Oil Products Company and Texaco Refining And Marketing, Inc. in jury trial and appeal involving alleged infringement of Union Oil Company of California’s patent directed to unleaded automotive gasoline).
Stryker Corp. v. Intermedics Orthodpedics, Inc., 891 F.Supp. 751 (E.D.N.Y., 1995) (Represented Stryker Corp. (“Stryker”) in a bench trial and appeal results in a $76 million award to Stryker for Intermedics willful infringement of Stryker’s patents directed to modular hip implants.)
Duracraft Corp. v. Honeywell, Inc., 881 F.Supp. 685 (D. Mass., 1994) (Represented Duracraft in a case settled by the parties involving Duracraft’s alleged infringement of Honeywell’s HEPA air purifier patent.)
North American Vaccine, Inc. v. American Cyanamid Co., 7 F.3d 1571 (Fed. Cir. 1993) (Represented North American Vaccine, Inc. (“NAVA”) in bench trial and appeal involving alleged infringement of NAVA’s patent directed to vaccines particularly suitable for immunizing human infants against infections).
Mobil Oil Corporation v. Amoco Chemicals Corporation, 779 F. Supp. 1429 (D. Del. 1991), aff’d, 980 F.2d 742 (Fed. Cir. 1992) (Represented Mobil Oil Corporation (“Mobil”) as a scientific advisor in bench trial and appeal involving infringement of Mobil’s patents directed to ZSM-5 catalysts and processes for conversion of hydrocarbons).

Publications & Presentations

Presentations and Publications - Legal

Speaker, "The International Trade Commission (ITC) As A Forum For Resolving Pharmaceutical Patent Disputes: What You Should Know,” Eino Nelson Research Conference, Florida (March 2007).
Speaker, “Procedural, Tactical And Ethical Issues To Consider If The Same Firm Is Engaged To Provide Both Non-Infringement/Invalidity Opinions And To Act As Lead Trial Counsel,” New York Intellectual Property Law Association (NYIPLA) 2006 CLE Fall One-Day Program (November 17, 2006).
Speaker, “Pre & Early Stage Patent Litigation,” Topic: “Provisional Remedies: Using Motions for TRO and Preliminary Injunctions.” Law Seminars International Workshop (June 21, 2005).
Speaker, “Pre & Early Stage Patent Litigation,” Topic: “Taking the Dispute Back to the Patent Office: Reexamination Strategies.” Law Seminars International Workshop (October 20, 2004).
Executive Briefing Organizer/Speaker, “Patenting Biotechnology Inventions: An International Perspective,” Topic: “Updates on International Biotech Patent Practice.” SMI Conference Executive Briefing (March 31, 2004).
Speaker, “The Hatch-Waxman Act Recent Legislative and Legal Developments,” 7th Annual SMI Conference Generics, Supergenerics & Patent Strategies Conference (29 & 30 March 2004).
Panel Moderator/Speaker, “The Prior Invention Defense: The Legal Reward For Good Business Practices,” NYIPLA CLE Fall One-Day Program (November 21, 2003).
Panel Moderator/Speaker, “Inequitable Conduct And The Duty Of Candor And Good Faith To The United States Patent Office: Issues Arising From Recent Federal Circuit Cases,” 17th Annual DuPont Intellectual Property CLE Seminar (October 27, 2003).
Speaker, “Successfully Navigating The Changing Waters For Generics And SuperGenerics In The U.S,” 6th Annual SMI Conference, London, England (March 30 & 31st, 2003).
Panel Moderator/Speaker, “Pharma Business Intelligence Summit,” Topic: “Protecting Property Rights—Patents, Trade Secrets, Trademarks and Confidential Information.” Iselin, New Jersey (September 19-20, 2002).
Speaker, “5th Annual Event Super Generics and Patent Busting,” Topic: “Intellectual Property Rights and Strategies: US Perspectives And Implications.” London, England (April 14-15, 2002).
Speaker, “Patent Litigation 2001,” Topic “Inequitable Conduct and Other Ethical Issues.” Atlanta PLI Course(October 9-10th, 2001).
Panel Moderator/Speaker, “Pharma and Biotech Business Intelligence Summit,” Topic: “Strategies for Successfully Navigating Legal and Ethical Pitfalls While Getting The Information You Need.” Princeton, New Jersey (June 14-15, 2001).
Speaker, “4th Annual Event Super Generics and Patent Busting,” Topic: “Intellectual Property Rights and Strategies For Generics and Super Generics: A USA Perspective.” London, England (April 23-24, 2001).
Speaker, “Intellectual Property Rights: A Global Perspective For The Drug Industry,” Topic: “Working With Patent Protection And IP Rights Within The Pharmaceutical Industry: A USA Perspective.” London, England (December 13-14, 2000).
Co-Author (with Stephen R. Smith) of an invited paper entitled “Limits of the Patent Law: When is the Requirement for Eligible Subject Matter Met?” Presented at the Seventeenth Annual Mid-Winter Institute of the AIPLA ( January 1994).

Presentations and Publications - Technical

Co-Author, “Cyclooctatetraenyllanthanoid Complexes. (C8H8)LuCl(THF) and (C8H8)Lu[?-C6H4CH2N(CH3)2](THF),” Inorg. Synth., Vol., 27. Wiley-Interscience (1990).
Co-Author, “Mixed-Ligand Imidazole Complexes of Organo-lanthanides,” Andrea L. Wayda, Martin L. Kaplan, Alan M. Lyons and Robin D. Rogers, Polyhedron (1990).
Co-Author, “Lanthanide-Imidazole Complexes as Latent Curing Agent for Epoxy Resins,” Martin L. Kaplan, Andrea L. Wayda and Alan M. Lyons, J. of Polymer Science, Part A: Polym. Chem. 28, 731 (1990).
Co-Author, “Mono-, Bis- and ris-(t-butylcyclopentadienyl) Lanthanoid Complexes,” Andrea L. Wayda, J. Organomet. Chem., (1989).
Co-Author, “The Low Temperature Synthesis of Zirconium and Hafnium Borides (MB2) by Thermal Decomposition of the Metal Borohydrides (M[BH4]4),” Andrea L. Wayda, Lynn F. Schneemeyer and Robert A. Opila, Appl. Phys. Lett., 53 (5), 361 (1988).
Co-Author, “Lanthanoid-Olefin Complex Formation: A Matrix Isolation Ultraviolet-Visible and Infrared Study of the Direct Synthesis of (C2H4)nEu Using Europium Atoms,” Mark P. Andrews and Andrea L. Wayda, Organometallics, 7, 743 (1988).
Co-Author, “Divalent Lanthanoid Synthesis in Liquid Ammonia. 2. The Synthesis and X-ray Crystal Structure of (C8H8)Yb(C5H5N)3 ½ C5H5N,” Andrea L. Wayda, Ishita Mukerji, James L. Dye and Robin D. Rogers, Organometallics, 6, 1328, (1987).
Co-Author, “Luminescence Studies of Tris(bis(trimethylsilyl(amido) terbium (III) and of its Adduct Complexes,” Harry G. Brittain, Andrea L. Wayda and Ishita Mukerji, Inorg. Chem., 26, 2472 (1987).
Co-Author, “Cyclooctatetraenide Derivatives of Divalent Samarium,” Andrea L. Wayda, Suzanne Cheng and Ishita Mukerji, J. Organomet. Chem. 330, C17 (1987).
Co-Author, “Multipurpose Vacuum Line Designs for Use in Synthetic Organometallic Chemistry,” Andrea L. Wayda, Patricia A. Bianconi and James L. Dye, ACS Symposium Series No. 357: “Experimental Organometallic Chemistry: A Practicum in Synthesis and Characterization.” A.L. Wayda and M.Y. Darensbroug, Eds. The American Chemical Society (1987).
Co-Author, “Greaseless Stillheads for Sensitive Solvent Purification,” Andrea L. Wayda and Patricia A. Bianconi, ACS Symposium Series No. 357, “Experimental Organometallic Chemistry: A Practicum in Synthesis and Characterization.” A.L. Wayda and M.Y. Darensbroug, Eds., The American Chemical Society, (1987).
Co-Author, "Epoxides With New Organoyttrium and Organolanthanoid Reagents,” Ishita Mukerji, Andrea L. Wayda, Gary Dabbagh and Steven H. Bertz, Angew. Chem. Int. Ed. Engl., 25, 760 (1986).
Co-Author, “A Versatile System for Vacuum-Line Manipulations”, Andrea L. Wayda and James L. Dye, J. Chem. Educ., 62, 356 (1985).
Co-Author, “The Synthesis, X-ray Crystal Structures and Reaction Chemistry of Homoleptic and Heteroleptic Organolanthanoid Complexes Incorporating the N,N-Dimethylamino-methylpheyl Ligand, “ Andrea L. Wayda and Robin D. Rogers, Organometallics, 4, 1440 (1985).
Co-Author, “Formation of Polynuclear Chlorometallates by the Reduction of Transition Metal Chlorides with Samarium Metal Slurries: Preparation and EXAFS Structure of SmNb3Cl14,” Alvin P. Ginsberg and Andrea L. Wayda, Inorg. Chem., 24, 4749 (1985).
Co-Author, “Homoleptic Organolanthanoid Hydrocarbyls. The Synthesis and X-ray Crystal Structure of Tris(?-(dimethylamino)phenyl)lutetium,” Andrea L. Wayda, Jerry L. Atwood and William E. Hunter, Organometallics, 3, 939 (1984).
“Luminescence Spectra of the Tetrahydorfuran Adducts of TbCl3,” Harry G. Brittain and Andrea L. Wayda, Inorg. Chim. Acta, 95, L1 (1984).
Co-Author, “Divalent Lanthanoid Synthesis in Liquid Ammonia. 1. The Synthesis and X-ray Crystal Structure of (C5Me5)2Yb(NH3)(THF),” Andrea L. Wayda, James L. Dye and Robin D. Rogers, Organometallics, 3, 1605 (1984).
Co-Author, “Cyclooctatetraenyllanthanide Complexes. 1. Alkyl and Arylmonocycloocatatetraenyllutetium Derivatives,” Andrea L. Wayda, Organometallics, 2, 565 (1983).
Co-Author, “Organolanthanide Hydride Chemistry. 1. Synthesis and X-ray Crystallographic Characterization of Dimeric Organolanthanide and Organoyttrium Hydride Compleses,” William J. Evans, James H. Meadows, Andrea L. Wayda, William E. Hunter and Jerry L. Atwood, J. Am Chem. Soc., 104, 2008 (1982).
Co-Author, “Organolanthanide Hydride Chemistry. 2. Synthesis and X-ray Crystallographic Characterization of a Trimetallic Organolathanide Polyhydride Complex,” William J. Evans, James H. Meadows, Andrea L. Wayda, William E. Hunter and Jerry L. Atwood, J. Am. Chem. Soc., 104, 2015 (1982).
Co-Author, “A Simple, Inexpensive Syntheses of Dipotassium Cyclooctatetraenide,” William J. Evans, Donald J. Wink, Andrea L. Wayda and David A. Little, J. Org. Chem., 46, 3925 (1981).
Co-Author, “Heteroleptic Tert-Butyl Lanthanoid Complexes. Synthesis and X-ray Crystal Structure of Monomeric Bis(cyclopentadienyl)lutetium Tetrahydrofuranate,” William J. Evans, Andrea L. Wayda, William E. Hunter and Jerry L. Atwood, J. Chem. Soc., Chem. Commun., 292 (1981).
Co-Author, “Organolanthanoid Activation of Carbon Monoxide: Single and Multiple Insertion of Carbon Monoxide into Tert-Butyl Lanthanoid Bonds: X-ray Crystallographic Identification of a New Bonding Mode of a Bridging Enedione Diolate Ligand Formed by Formal Coupling of Four Carbon Monoxide Molecules,” William J. Evans, Andrea L. Wayda, William E. Hunter and Jerry L. Atwood, J. Chem. Soc., Chem. Commun., 706 (1981).
Co-Author, “Synthesis and Crystallographic Characterization of a Dimeric Alkynide Bridged Organolanthanide: ((C5H5)2ErC C (CH3)3)2,” Jerry L. Atwood, William E. Hunter, Andrea L. Wayda and William J. Evans, Inorg. Chem., 20, 4115 (1981).
Co-Author, “Chemical Reactivity of Lanthanide Metal Carbon ? Bonds: Tert-Butyl Lanthanide Complexes as Synthetic Precursors to Lanthanide Alkynides,” William J. Evans and Andrea L. Wayda, J. Organomet. Chem., 202, C6 (1980).
Co-Author, “Syntheses of a Bis(pentamethlcyclopentadienyl) Derivative of Neodymium,” Andrea L. Wayda and William J. Evans, Inorg. Chem., 19, 2190 (1980).
Co-Author, “Syntheses and Raman Spectra of Nitrosyl Fluorometallate Salts,” Walter A. Sunder, Andrea Wayda, Doreen DiStefano, Warren E. Falconer and James E. Griffiths, J. Fluor. Chem., 14, 299 (1979).
“Homogeneous Catalytic Activation of Molecular Hydrogen by Lanthanoid Metal Complexes,” William J. Evans, Steven C. Engerer, Pamela A. Piliero and Andrea L. Wayda, J. Chem. Soc., Chem. Commun., 1007 (1979).
Co-Author, “Organometallic Chemistry of the Lanthanides Under Reductive Conditions,” William J. Evans, Steven C. Engerer, Pamela Piliero and Andrea L. Wayda, “Fundamental Research in Homogeneous Catalysis,” M. Tsutsui, Ed. Plenum Publishing Corp., 3, 941 (1979).
Co-Author, “Nonaqueous Reductive Lanthanide Chemistry. 2. Conversion of cis, cis-1, 5-Cyclooctadiene to Cyclooctatetraenyl Dianion by Reduced Praseodymium and Potassium,” William J. Evans, Andrea L. Wayda, Chia-Wun Chang and William M. Cwirla, J. Am. Chem. Soc., 100, 333 (1978).
Co-Author, “Syntheses and Thermal Decomposition of Homoleptic Tert-Butyl Lanthanide Complexes,” Andrea L. Wayda and William J. Evans, J. Am. Chem. Soc., 100, 7119 (1978).
Co-Author, “Models for the Role of Magnesium in Enzymic Catalysis. The Effect of Magnesium Ion on the General Base Catalyzed Enolization of Methyl Acetonylphosphonate,” Ronald J. Kluger and Andrea Wayda, Can. J. Chem., 53, 2354 (1975).